EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis

Heqiao Han, Lian Li, Taiwon Park, Yuzhao Yang, Guha Alai, Chuan Zhong, Yidan Lin

Frontiers in Oncology · 20.04.2026 · 16

DOI: 10.3389/fonc.2026.1820515 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 20.04.2026. Verfasst von Heqiao Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery department, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligometastatic non-small cell lung cancer (NSCLC) represents a potentially modifiable stage of metastatic disease, however, the survival benefit of local consolidative therapy (LCT) in patients without actionable driver mutations remains uncertain in the era of immunotherapy. To address this clinically relevant controversy, we performed a systematic review and meta-analysis evaluating the efficacy and safety of adding LCT to systemic therapy in driver-negative oligometastatic NSCLC. A comprehensive search of PubMed, Embase, and the Cochrane Library through December 2025 identified 13 eligible studies including 1,698 patients. Pooled analyses demonstrated that the addition of LCT was significantly associated with improved overall survival (HR 0.45, 95% CI 0.36-0.56) and progression-free survival (HR 0.53, 95% CI 0.46-0.61) compared with systemic therapy alone. Notably, cumulative meta-analysis showed that the survival advantage remained stable as evidence accrued over time, underscoring the consistency of the treatment effect. LCT was also associated with a higher objective response rate (RR 1.47, 95% CI 1.12-1.93) without a significant increase in treatment-related adverse events (RR 1.31, 95% CI 0.93-1.84). Importantly, subgroup analyses demonstrated that the survival benefit persisted in studies incorporating immunotherapy-based regimens, suggesting that LCT retains clinical value even within contemporary systemic treatment paradigms. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. Collectively, these results indicate that integrating LCT into systemic therapy is associated with meaningful survival gains in driver-negative oligometastatic NSCLC without added toxicity, supporting a risk-adapted, multidisciplinary treatment strategy in the modern immunotherapy era. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420261351878.

Schlagwörter

Stichwörter der Autor:innen

driver-negativeimmunotherapylocal consolidative therapymeta-analysisoligometastatic non-small cell lung cancer

Autor:innen und Institutionen

  • Thoracic Surgery department, West China Hospital, Sichuan University, Chengdu, China.
  • Outpatient department, West China Hospital, Sichuan University, Chengdu, China.

Zitieren

APA

Han, H., Li, L., Park, T., Yang, Y., Alai, G., Zhong, C., & Lin, Y. (2026). Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1820515

Vancouver

Han H, Li L, Park T, Yang Y, Alai G, Zhong C, et al. Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1820515

BibTeX
@article{Han2026,
  author = {Han, Heqiao and Li, Lian and Park, Taiwon and Yang, Yuzhao and Alai, Guha and Zhong, Chuan and Lin, Yidan},
  title = {Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1820515}
}
Kostenlos starten →